Estimating the Factor VIII‐Equivalent Activity of Emicizumab Using Global Assays of Haemostasis
Sign Up to like & getrecommendations! Published in 2025 at "Haemophilia"
DOI: 10.1111/hae.70085
Abstract: Emicizumab is a bispecific monoclonal antibody mimicking factor (F) VIII activity and an effective therapy for prophylaxis in people with haemophilia A (PWHA). The FVIII‐equivalent activity (FVIIIeq) of emicizumab remains unknown. read more here.
Keywords: estimating factor; factor viii; emicizumab; equivalent activity ... See more keywords